Clinical Study | Office of Clinical Research

This Study Will Look At The Safety Of Sodium Benzoate, And At How Well It Works In Improving Symptoms Of Schizophrenia When Added To Current Medication

Posted Date: Jan 28, 2020

Investigator: Caleb Adler
Specialties:
Type of Study: Drug

AN ADAPTIVE, PHASE IIB/III, MULTI-CENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF NABEN® (SODIUM BENZOATE), A D-AMINO ACID OXIDASE INHIBITOR, AS AN ADD-ON TREATMENT FOR SCHIZOPHRENIA IN ADULTS

Criteria:

Men And Women 18-45 Years Old Who Have Been Diagnosed With Schizophrenia For At Least 2 Years

Keywords:

Schizophrenia, Adults

For More Information:

Karen Tugrul, Rn
513-558-6831
tugrulkc@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List